Research programme: CD14/TLR4 antagonists - InnaxonAlternative Names: IAXO small molecules - Innaxon; IAXO-101 - Innaxon; IAXO-102 - Innaxon
Latest Information Update: 01 Aug 2016
At a glance
- Originator Unknown
- Developer Innaxon
- Class Benzylammonium compounds; Glycolipids; Small molecules
- Mechanism of Action CD14 antigen inhibitors; Toll-like receptor 4 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 01 Aug 2016 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (unspecified route)